February 28, 2015 1:54 AM ET


Company Overview of Aventis S.A.

Company Overview

As of August 30, 2004, Aventis S.A. was acquired by Sanofi-Synthelabo S.A. Aventis S.A. is engaged in the discovery, development, manufacture, and marketing of branded prescription drugs and human vaccines. Its products were used for treating lung and breast cancer, thrombosis, seasonal allergies, diabetes and hypertension in the European Union, the United States, and the Asia-Pacific region. Aventis S.A. was founded in 1900 and is based in Strasbourg, France.

Espace Europeen de l'Entreprise

16 avenue de l'Europe Cedex 9

Strasbourg,  67917


Founded in 1900

75,567 Employees


33 3 88 99 11 00


33 1 47 68 19 11

Key Executives for Aventis S.A.

Aventis S.A. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Pharm'Up Laboratoires Europe
Famar Orleans Europe
Novaclone sarl Europe
Capgene Europe
Laboratoire Mediligne SA Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aventis S.A., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.